Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763998 | 0.92 | USP2 (0.36) | USP2RORCALDH1A1TP53ALOX15 | |
| SCHEMBL5118182 | 0.89 | BDKRB1 (0.36) | RORCALDH1A1F10LMNABDKRB1 | |
| SCHEMBL5110842 | 0.87 | BDKRB1 (0.34) | RORCF10BDKRB1 | |
| SCHEMBL6764299 | 0.86 | BDKRB1 (0.46) | USP2RORCTP53ALOX15TSHR | |
| SCHEMBL5111163 | 0.86 | BDKRB1 (0.40) | RORCALDH1A1F10BDKRB1 | |
| SCHEMBL6764171 | 0.85 | KMT2A (0.32) | ALDH1A1TP53LMNAMEN1KMT2A | |
| SCHEMBL5111911 | 0.81 | BDKRB1 (0.34) | RORCALDH1A1BDKRB1MEN1KMT2A | |
| SCHEMBL5124978 | 0.80 | BDKRB1 (0.33) | RORCALDH1A1F10LMNABDKRB1 | |
| SCHEMBL6761755 | 0.80 | KMT2A (0.37) | ALDH1A1TP53LMNAMEN1KMT2A | |
| SCHEMBL6762507 | 0.80 | DAGLA (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | USP2 2448/4885RORC 3349/4885ALDH1A1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.